Watch-and-wait after chemo-radiation plus immunotherapy for esophagus cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 study tests whether adding an immunotherapy drug (camrelizumab) to standard chemo-radiation can help some people with operable esophagus cancer avoid immediate surgery, using a “watch and wait” approach. If it works, it may reduce the need for early surgery for carefully selected patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign consent and you’re able to follow the study visits, treatments, and lab tests
- Your cancer is esophageal cancer in the chest area, and it is operable but not advanced/spotty in a way that makes it unresectable or metastatic
- Your cancer has measurable tumor on scans and you have tumor tissue available for PD-L1 testing
- Your overall health status is good (ECOG 0–1) and your surgeon believes you can safely remove the tumor
- You have acceptable blood test results (white blood cells, platelets, hemoglobin, and liver/kidney tests are high enough)
- You have no major problems that would make treatment or surgery unsafe (like recent chest radiation/chemo/immunotherapy/surgery for this area)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This trial tests a treatment plan that combines chemotherapy and immunotherapy before surgery, followed by radiation and immunotherapy after surgery for people with esophageal squamous cell cancer. It aims to see if this approach helps prevent the cancer from coming back.
This trial studies giving immunotherapy (anti–PD-1) together with chemotherapy before surgery for certain locally advanced esophageal squamous cell cancer. The goal is to improve how well the tumor responds before and after the operation.
This trial tests a new approach for people with a certain type of esophageal cancer. Instead of surgery right away, you would receive chemotherapy, radiation, and an immunotherapy drug called adebrelimab. After that, doctors will closely watch your cancer to see if it's gone. The goal is to avoid surgery if the treatment works well.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.